Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain

Published: August 30, 2011
Category: Bibliography > Papers
Authors: Navarro-Artieda R, Planas-Comes A, Rejas-Gutierrez J, Sicras-Mainar A
Countries: Spain
Language: null
Types: Care Management
Settings: Health Plan, Hospital

J Eval Clin Pract 18:1170-1179.

Badalona Serveis Assistencials, Badalona, Barcelona, Spain

OBJECTIVE: To compare the cost of adding either pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain (PNP).

METHODS: A retrospective observational study was conducted using medical records from a Spanish health care provider claims database. Patients receiving health care for PNP, above 18 years and for which either pregabalin or gabapentin was initiated between 2006 and 2008 were included. Economic evaluation included health care resource utilization costs and costs due to sick leave.

RESULTS: A total of 1163 patients with PNP were eligible for analysis: 764 were prescribed pregabalin and 399 gabapentin in addition to current pain therapy. Mean age was 59.2 years and 62.2% were female. Concomitant use of analgesics was higher in the gabapentin cohort (3.2 vs. 2.7; P = 0.003), mainly due to non-steroidal anti-inflammatory drugs (74.9% vs. 69.5%; P = 0.018) and opioids (27.7% vs. 17.9%; P = 0.031). Adjusted total costs per patient was lower in pregabalin-treated patients (€2514 vs. €3241; P = 0.003), due to less sick leave (€1067 vs. €1633; P = 0.018) and lower health care costs (€1447 vs. €1609; P = 0.004). The higher acquisition cost of pregabalin (€351 vs. €191; P < 0.001) was largely compensated with lower costs in medical visits, physiotherapy, hospital stays and concomitant analgesics.

CONCLUSIONS: In community-treated patients with PNP, total costs were considerably less for those patients initiated with pregabalin therapy than for those patients starting gabapentin add-on therapy. The relatively higher treatment acquisition cost of pregabalin was largely compensated by the overall lower costs for the other components of health care resources and sick leave, thus reducing the economic impact on the health care provider’s budget and society.

PMID: 21883712

Medications,Cost Burden Evaluation,Prescription Drugs and Expenditures,Spain,Resource Use,Aged,Amines/therapeutic use,Analgesics/therapeutic use,Analgesics,Opioid/economics,Analgesics,Opioid/therapeutic use,Anti-Inflammatory Agents,Non-Steroidal/economics,Anti-Inflammatory Agents,Non-Steroidal/therapeutic use,Co-morbidity,Cost-Benefit Analysis,Cyclohexanecarboxylic Acids/therapeutic use,Health Services/economics,Health Services/utilization,Gender,Middle Aged,Pregabalin,Retrospective Studies,Socioeconomic Factors,gamma-Aminobutyric Acid/economics,gamma-Aminobutyric Acid/therapeutic use

Please log in/register to access.

Log in/Register

LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top